Inactivation of Phosphoserine/Threonine Phosphatase PstP in H37Rv Mycobacterium tuberculosis by In silico Drug Design Approach

Introduction: Mycobacterium tuberculosis (Mtb) is the aetiological agent of the infectious disease tuberculosis (TB). According to the World Health Organization’s most recent study, kinases play a crucial role in phosphorylation by transferring phosphate moieties to target proteins, while phosphatases reverse this process by dephosphorylating substrates or regulating kinase activity, restoring proteins to their unphosphorylated state.Method: Several software, programs and databases were used to predict and calculate the interaction between target protein and ligand molecules.Results: Protein phosphatases are essential components in cellular signalling pathways mediated by phosphorylation. Despite the presenceof eleven serine/threonine protein kinases in Mtb, only one of them, namely phosphoserine/threonine phosphatase (PstP), has been identified. PstP stands out as a promising drug target due to its singular role as the exclusive phosphatase in Mtb. Serine/threonine protein phosphatase (PDB ID: 2cm1) was docked using AutoDock Vina software with ligands collected from other studies conducted on Mycobacterium tuberculosis. Virtual screening was carried out using ZincPharmer to find the homologous molecules to load the pharmacophore.Conclusion: Mycobacterium tuberculosis H37Rv has multiple targets for new drug design procedures. This is due to the variation in the proteins. PstP protein has five pockets and was given a good docking score with eight safe inhibitors for further studies, and eight tested molecules with PubChem_IDs 50956528, 7388777, 46780845, 3635532, 46954451, 1494562, 540267, 79107978, which have good features and can bind to PstP protein. How to cite this article:Abdul Jalil A A, Yaseen O Q, Khalaf S N. Inactivation of Phosphoserine/Threonine Phosphatase PstP in H37Rv Mycobacterium tuberculosis by In silico Drug Design Approach. J Commun Dis. 2024;56(3):74-80. DOI: https://doi.org/10.24321/0019.5138.202452

Authors

Institutions

Publication Details

Journal
JOURNAL OF COMMUNICABLE DISEASES
Published
2024-10-11
DOI
https://doi.org/10.24321/0019.5138.202452
Primary Topic
Biochemical and Molecular Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inactivation of Phosphoserine/Threonine Phosphatase PstP in H37Rv Mycobacterium tuberculosis by In silico Drug Design Approach

Asra’a Adnan Abdul-Jalil
JOURNAL OF COMMUNICABLE DISEASES
Biochemical and Molecular Research
article

Inactivation of Phosphoserine/Threonine Phosphatase PstP in H37Rv Mycobacterium tuberculosis by In silico Drug Design Approach

Asra’a Adnan Abdul-Jalil
article en

Abstract

Introduction: Mycobacterium tuberculosis (Mtb) is the aetiological agent of the infectious disease tuberculosis (TB). According to the World Health Organization’s most recent study, kinases play a crucial role in phosphorylation by transferring phosphate moieties to target proteins, while phosphatases reverse this process by dephosphorylating substrates or regulating kinase activity, restoring proteins to their unphosphorylated state.Method: Several software, programs and databases were used to predict and calculate the interaction between target protein and ligand molecules.Results: Protein phosphatases are essential components in cellular signalling pathways mediated by phosphorylation. Despite the presenceof eleven serine/threonine protein kinases in Mtb, only one of them, namely phosphoserine/threonine phosphatase (PstP), has been identified. PstP stands out as a promising drug target due to its singular role as the exclusive phosphatase in Mtb. Serine/threonine protein phosphatase (PDB ID: 2cm1) was docked using AutoDock Vina software with ligands collected from other studies conducted on Mycobacterium tuberculosis. Virtual screening was carried out using ZincPharmer to find the homologous molecules to load the pharmacophore.Conclusion: Mycobacterium tuberculosis H37Rv has multiple targets for new drug design procedures. This is due to the variation in the proteins. PstP protein has five pockets and was given a good docking score with eight safe inhibitors for further studies, and eight tested molecules with PubChem_IDs 50956528, 7388777, 46780845, 3635532, 46954451, 1494562, 540267, 79107978, which have good features and can bind to PstP protein. How to cite this article:Abdul Jalil A A, Yaseen O Q, Khalaf S N. Inactivation of Phosphoserine/Threonine Phosphatase PstP in H37Rv Mycobacterium tuberculosis by In silico Drug Design Approach. J Commun Dis. 2024;56(3):74-80. DOI: https://doi.org/10.24321/0019.5138.202452

JOURNAL OF COMMUNICABLE DISEASESVol. 56(03)
University of Anbar (IQ)
Good health and well-being
Openalex Percentile: Top 84%
Biochemical and Molecular Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.